Form 4: Medpace Exec Plans $12.18M Stock Sale

Medpace Holdings' Executive VP of Operations, Susan E. Burwig, filed a Form 4 indicating a planned sale of 20,000 shares of common stock on November 24, 2025, for an average price of $609.15, executed under a Rule 10b5-1 plan.

Summary

• Susan E. Burwig, Executive VP of Operations at Medpace Holdings, Inc. (MEDP), reported a planned disposition of 20,000 shares of common stock.
• The transaction is scheduled for November 24, 2025, and was effected pursuant to a limit order placed by the Reporting Person during an open window period, consistent with a Rule 10b5-1(c) plan.
• The shares are to be sold at a weighted average price of $609.15 per share, with individual transactions ranging from $607.59 to $610.92.
• The total value of the planned sale is approximately $12,183,000.
• Following this planned transaction, Ms. Burwig will beneficially own 27,500 shares of Medpace Holdings, Inc. common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a Rule 10b5-1 plan, which generally mitigates the negative implications of insider selling as it is not based on new material non-public information. However, it still represents a reduction in executive ownership.

Negatives

• While a planned sale under a Rule 10b5-1 plan, the disposition of a significant number of shares by an executive could still be viewed by some investors as a signal, even if not based on new material non-public information.

Future Outlook

The filing details a pre-planned future transaction under a Rule 10b5-1 plan, indicating an executive's intent to sell shares on a specific future date. It does not provide any forward-looking statements regarding company performance or strategic direction.

Industry Context

Insider transactions, particularly planned sales under Rule 10b5-1, are common across all industries. For a Contract Research Organization (CRO) like Medpace, such a filing primarily reflects an executive's personal financial planning rather than a direct commentary on industry trends or competitive positioning, although the market may still react to the news.

Stakeholder Impact

• Shareholders may interpret the planned executive stock sale as a signal, potentially influencing market sentiment, even though it is a pre-arranged transaction under a 10b5-1 plan for personal financial management.

Key Dates

Keywords

Medpace Holdings, MEDP, Insider Trading, Form 4, Stock Sale, Executive Compensation, 10b5-1 Plan, Common Stock